Winter 2013

University of Michigan Comprehensive Cancer Center Cancer News
Graft-vs-Host-Disease cells

New drug cuts risk of deadly transplant side effect in half

A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center. more

A Lifeline in Hard Times

When Aracelli and Miguel Martinez left Mexico City for Michigan 30 years ago, health insurance was the last thing on their minds as the healthy couple and their two children began new lives in the Midwest. more

Aracelli and Miguel Martinez

More News

image of breast cancer survivors

Cognitive problems may be present before 'chemobrain' in women with breast cancer

Women undergoing chemotherapy who experience cognitive problems, commonly referred to as "chemobrain," displayed alterations in neurocognitive responses prior to undergoing treatment. more

Image of bone scans

Drug shows promise in prostate cancer spread to bone

A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a study reported by University of Michigan Comprehensive Cancer Center researchers. more

Investigating how patients, doctors make breast cancer treatment decisions

Limiting advanced imaging tests such as CT scans for patients with early stage breast cancer could improve the quality and reduce the cost of care. more

image of DNA

Anti-aging gene identified as tumor suppressor

A new study sheds more light on how an anti-aging gene suppresses cancer growth, joint University of Michigan Health System and Harvard Medical School research shows. more

Stay Connected

Twitter Facebook YouTube mCancerTalk Thrive Newsletter Medicine at Michigan magazine
 

Director's Letter

Welcome to the winter edition of the U-M cancer e-newsletter. more

Max S. Wicha, M.D.

The Michigan Difference

A team of national leaders treating complex and rare cases.

Elena Stoffel, MD

Dr. Elena Stoffel discusses cancer genetics and skin cancer

 

Media Coverage

More media coverage…

Get Involved

Knit to Support Cancer
The annual Knit Michigan event Feb. 2 is designed to bring together fellow fiber enthusiasts to support cancer patients and their families. Learn more

Trivia Night
Join others for a night of trivia, pizza, prizes and drawings at the annual Tim O'Brien Trivia Night in Dearborn on March 23. Learn more

iPads Help Cancer Patients Wile Away the Hours
ComfortApp, a student-run organization, has been raising funds to allow the UMCCC to loan iPads to cancer patients undergoing treatment. The devices help to make the time pass more enjoyably, and help patients stay connected to family and friends. Learn more

More events…
Plan your own event…

© 2013 The Regents of the University of Michigan Non-discrimination policy
If you'd prefer not to receive this email, click here to unsubscribe.

A Lifeline in Hard Times

Donor-supported resources help patients focus on healing

When Aracelli and Miguel Martinez left Mexico City for Michigan 30 years ago, health insurance was the last thing on their minds as the healthy couple and their two children began new lives in the Midwest. Fast forward to May 2009: their children grown, Aracelli worked as a caregiver to the elderly, Miguel managed the grounds and home of a family with a large property. The couple had lived in their Auburn Hills home for a decade.

Anti-aging gene identified as tumor suppressor

A new study sheds more light on how an anti-aging gene suppresses cancer growth, joint University of Michigan Health System and Harvard Medical School research shows.

Loss of the SIRT6 protein in mice increases the number, size and aggressiveness of tumors, according to the new research published in the scientific journal Cell. The study also suggests that the loss of SIRT6 promotes tumor growth in human colon and pancreatic cancers.

New drug cuts risk of deadly transplant side effect in half

A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.

The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 21% of patients developing graft-vs.-host disease compared to 42% of patients who typically develop this condition with standard medications alone.

A Message From Our Director

Welcome to the winter edition of the University of Michigan Comprehensive Cancer Center's electronic newsletter. I'm pleased to be able to share with you some of the interesting and exciting ways that the UMCCC continues to make great strides in understanding, diagnosing, preventing and treating cancer.

Subscribe to RSS - Winter 2013